Document Detail


Zinc deficiency anemia and effects of zinc therapy in maintenance hemodialysis patients.
MedLine Citation:
PMID:  19527468     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Quantitative adjuvant zinc therapy using polaprezinc was performed to examine the correlation between zinc concentration and anemia in maintenance hemodialysis patients to propose appropriate treatment. Anemia and serum zinc concentration were measured in 117 patients with chronic renal failure receiving outpatient maintenance hemodialysis at Tsuyama Chuo Kinen Hospital. Two bags of polaprezinc (containing zinc 34 mg/day) were administered to 58 patients with lower than normal zinc levels (Zn < 80 mg/dl) as adjuvant zinc therapy to assess anemia improvement. Zinc concentration and all anemia parameters showed significant positive correlation, indicating that anemia improves in patients with high serum zinc levels. Regarding the effects of adjuvant zinc therapy for improving anemia, hemoglobin levels were found to increase significantly to the highest value at 3 weeks. During treatment, the dosage of erythropoietin was reduced significantly from baseline at all assessment points. No zinc poisoning from therapy was seen, but two patients had diarrhea (1.9%). Zinc-treated patients required iron therapy due to the development of iron deficiency. Most maintenance hemodialysis patients suffer from zinc deficiency anemia, and zinc-based polaprezinc has been confirmed to be an effective and safe adjuvant zinc treatment. Most patients diagnosed as refractory anemia with no response to erythropoietin also suffer from zinc deficiency anemia, many of whom are expected to benefit from zinc therapy to improve their anemia. Possible zinc deficiency anemia should be considered in the treatment of refractory anemia with no response to erythropoietin.
Authors:
Tatsuo Fukushima; Hideyuki Horike; Shigeatsu Fujiki; Shingo Kitada; Tamaki Sasaki; Naoki Kashihara
Related Documents :
17207238 - Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopen...
17029128 - No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid...
836118 - The pathophysiology and clinical characteristics of severe hypophosphatemia.
2007928 - Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
3480238 - Splenic function in chronic myelogenous leukemia.
12727578 - Evidence of autoimmunity in chronic periaortitis: a prospective study.
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy     Volume:  13     ISSN:  1744-9987     ISO Abbreviation:  Ther Apher Dial     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-16     Completed Date:  2009-08-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101181252     Medline TA:  Ther Apher Dial     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  213-9     Citation Subset:  IM    
Affiliation:
Department of Medicine, Tsuoyama Chuo Hospital, 71 Nikaimachi, Tsuyama, Okayama, Japan. fuku@tch.or.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anemia / drug therapy*,  etiology
Anemia, Iron-Deficiency / drug therapy,  etiology
Carnosine / adverse effects,  analogs & derivatives*,  therapeutic use
Diarrhea / chemically induced
Dose-Response Relationship, Drug
Erythropoietin, Recombinant / administration & dosage,  therapeutic use
Female
Follow-Up Studies
Hemoglobins / metabolism
Humans
Iron Compounds / administration & dosage
Japan / epidemiology
Kidney Failure, Chronic / therapy*
Male
Middle Aged
Organometallic Compounds / adverse effects,  therapeutic use*
Renal Dialysis / adverse effects*
Zinc / blood,  deficiency
Zinc Compounds / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Erythropoietin, Recombinant; 0/Hemoglobins; 0/Iron Compounds; 0/Organometallic Compounds; 0/Zinc Compounds; 107667-60-7/polaprezinc; 305-84-0/Carnosine; 7440-66-6/Zinc

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  C-C chemokine receptor 2 expression by circulating monocytes influences atherosclerosis in patients ...
Next Document:  Ionized alkaline water: new strategy for management of metabolic acidosis in experimental animals.